

Katja GoriÄar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/322185/publications.pdf>

Version: 2024-02-01

69
papers

898
citations

623734

14
h-index

580821

25
g-index

70
all docs

70
docs citations

70
times ranked

1547
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Applicability of Patient- and Clinician-Reported Outcome Tools in the Management of Patients with Acromegaly. <i>Endocrine Practice</i> , 2022, , .	2.1	3
2	Genetic Variability of Inflammation and Oxidative Stress Genes Affects Onset, Progression of the Disease and Survival of Patients with Amyotrophic Lateral Sclerosis. <i>Genes</i> , 2022, 13, 757.	2.4	9
3	The role of polymorphisms in glutathione-related genes in asbestos-related diseases. <i>Radiology and Oncology</i> , 2021, 55, 179-186.	1.7	0
4	CARD8 and IL1B Polymorphisms Influence MRI Brain Patterns in Newborns with Hypoxic-Ischemic Encephalopathy Treated with Hypothermia. <i>Antioxidants</i> , 2021, 10, 96.	5.1	7
5	Plasma Extracellular Vesicle Characteristics Correlate with Tumor Differentiation and Predict Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgery with Curative Intent. <i>Journal of Personalized Medicine</i> , 2021, 11, 77.	2.5	9
6	Factors associated with degraded trabecular bone score in heart transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14274.	1.6	2
7	Association of Genetic Polymorphisms in Oxidative Stress and Inflammation Pathways with Glaucoma Risk and Phenotype. <i>Journal of Clinical Medicine</i> , 2021, 10, 1148.	2.4	11
8	Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 646901.	3.4	16
9	Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology. <i>Frontiers in Pharmacology</i> , 2021, 12, 671298.	3.5	16
10	HIF1A polymorphisms do not modify the risk of epilepsy nor cerebral palsy after neonatal hypoxic-ischemic encephalopathy. <i>Brain Research</i> , 2021, 1757, 147281.	2.2	5
11	Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 43.	2.7	2
12	Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study. <i>Endocrine Connections</i> , 2021, 10, 637-645.	1.9	5
13	Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy. <i>Genes</i> , 2021, 12, 1057.	2.4	6
14	Systematic Search for Novel Circulating Biomarkers Associated with Extracellular Vesicles in Alzheimer's Disease: Combining Literature Screening and Database Mining Approaches. <i>Journal of Personalized Medicine</i> , 2021, 11, 946.	2.5	6
15	Genetic Polymorphisms, Gene-Gene Interactions and Neurologic Sequelae at Two Years Follow-Up in Newborns with Hypoxic-Ischemic Encephalopathy Treated with Hypothermia. <i>Antioxidants</i> , 2021, 10, 1495.	5.1	5
16	Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1014.	2.5	5
17	Serum Calretinin as a Biomarker in Malignant Mesothelioma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4875.	2.4	2
18	Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?. <i>Endocrine</i> , 2021, , 1.	2.3	3

#	ARTICLE	IF	CITATIONS
19	Asbestos-Related Diseases and Blood Biomarkers. , 2020, , .		0
20	The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patientsâ€™ stratification by body mass index and age. BMC Endocrine Disorders, 2020, 20, 118.	2.2	12
21	Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome. Metabolites, 2020, 10, 439.	2.9	16
22	Relationship between cardiorespiratory phase coherence during hypoxia and genetic polymorphism in humans. Journal of Physiology, 2020, 598, 2001-2019.	2.9	10
23	Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocrine Connections, 2020, 9, 44-54.	1.9	18
24	Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases. Radiology and Oncology, 2020, 54, 86-95.	1.7	16
25	The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma. Radiology and Oncology, 2020, 54, 429-436.	1.7	4
26	Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients. Disease Markers, 2020, 2020, 1-12.	1.3	5
27	An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity. Journal of International Medical Research, 2019, 47, 4691-4700.	1.0	7
28	DEPTOR polymorphisms influence late complications in Type 2 diabetes patients. Pharmacogenomics, 2019, 20, 879-890.	1.3	2
29	Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma. Disease Markers, 2019, 2019, 1-8.	1.3	8
30	Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children. Frontiers in Pediatrics, 2019, 7, 63.	1.9	8
31	Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients. Journal of Medical Biochemistry, 2019, 39, 276-282.	1.7	5
32	Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment. Radiology and Oncology, 2019, 53, 96-104.	1.7	7
33	The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma. Radiology and Oncology, 2019, 53, 206-212.	1.7	7
34	NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases. Journal of Medical Biochemistry, 2019, 39, 91-99.	1.7	4
35	<i>SLC6A4</i> Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2018, 2018, 1-7.	1.5	77
36	CYP2D6 phenotype and tramadol-related adverse events in breast cancer patients.. Journal of Clinical Oncology, 2018, 36, e22186-e22186.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. PLoS ONE, 2018, 13, e0191613.	2.5	76
38	The influence of genetic variability on the risk of developing malignant mesothelioma. Radiology and Oncology, 2018, 52, 105-111.	1.7	11
39	Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma. Radiology and Oncology, 2018, 52, 160-166.	1.7	14
40	Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma. Radiology and Oncology, 2018, .	1.7	0
41	Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocrine Disorders, 2017, 17, 5.	2.2	54
42	Antioxidant polymorphisms do not influence the risk of epilepsy or its drug resistance after neonatal hypoxic-ischemic brain injury. Seizure: the Journal of the British Epilepsy Association, 2017, 46, 38-42.	2.0	12
43	Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Scientific Reports, 2017, 7, 46537.	3.3	14
44	Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β -cell function and insulin sensitivity in metformin treated PCOS. Endocrine Research, 2017, 42, 261-268.	1.2	21
45	The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2017, 51, 9-13.	2.0	14
46	Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma. Disease Markers, 2017, 2017, 1-8.	1.3	13
47	Expression of miRNA and Occurrence of Distant Metastases in Patients with Hurthle Cell Carcinoma. International Journal of Endocrinology, 2016, 2016, 1-6.	1.5	12
48	<i>SORCS1</i> polymorphism and insulin secretion in obese women with polycystic ovary syndrome. Gynecological Endocrinology, 2016, 32, 395-398.	1.7	6
49	Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of <i>GPX1</i> polymorphism and recurrent Hurthle cell thyroid carcinoma. Radiology and Oncology, 2016, 50, 289-296.	1.7	7
50	The association between antioxidant enzyme polymorphisms and cerebral palsy after perinatal hypoxic-ischaemic encephalopathy. European Journal of Paediatric Neurology, 2016, 20, 704-708.	1.6	23
51	A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility. Pediatric Research, 2016, 80, 472-479.	2.3	13
52	Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study. Experimental and Therapeutic Medicine, 2016, 11, 1194-1200.	1.8	36
53	Expression of miRNA and occurrence of distant metastases in patients with Hurthle cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e17554-e17554.	1.6	1
54	Antioxidant defence-related genetic variants are not associated with higher risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescence. Radiology and Oncology, 2016, 50, 80-86.	1.7	3

#	ARTICLE	IF	CITATIONS
55	<i>NLRP3</i> Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-6.	2.3	42
56	Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma. <i>Disease Markers</i> , 2015, 2015, 1-8.	1.3	13
57	Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3103-3108.	1.3	24
58	Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma / Polimorfizam Gena Odgovornih Za Reparaciju Dnk Homolognom Rekombinacijom I Rizikza Pojavu Osteosarkoma. <i>Journal of Medical Biochemistry</i> , 2015, 34, 200-206.	1.7	6
59	Translesion Polymerase Genes Polymorphisms and Haplotypes Influence Survival of Osteosarcoma Patients. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 180-185.	2.0	12
60	Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. <i>Cancer Epidemiology</i> , 2015, 39, 182-188.	1.9	40
61	The association of folate pathway and DNA repair polymorphisms with susceptibility to childhood acute lymphoblastic leukemia. <i>Gene</i> , 2015, 562, 203-209.	2.2	13
62	Common polymorphisms in antioxidant genes are associated with diabetic nephropathy in Type 2 diabetes patients. <i>Personalized Medicine</i> , 2015, 12, 187-198.	1.5	9
63	The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	12
64	Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. <i>Radiology and Oncology</i> , 2014, 48, 163-172.	1.7	14
65	Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 514-521.	1.5	28
66	Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma. <i>Pharmacogenomics</i> , 2014, 15, 941-950.	1.3	15
67	Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage. <i>Radiology and Oncology</i> , 2012, 46, 46-53.	1.7	19
68	Current Mesothelioma Treatment and Future Perspectives. , 0, , .		0
69	Genetic variability in the cholecystokinin A receptor affects lipid profile and glucose tolerance in patients with polycystic ovary syndrome. <i>Archives of Medical Science</i> , 0, , .	0.9	0